Repositioning Candidate Details
| Candidate ID: | R0329 |
| Source ID: | DB01110 |
| Source Type: | approved; investigational; vet_approved |
| Compound Type: | small molecule |
| Compound Name: | Miconazole |
| Synonyms: | |
| Molecular Formula: | C18H14Cl4N2O |
| SMILES: | ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1 |
| Structure: |
|
| DrugBank Description: | An imidazole antifungal agent that is used topically and by intravenous infusion. |
| CAS Number: | 22916-47-8 |
| Molecular Weight: | 416.129 |
| DrugBank Indication: | For topical application in the treatment of tinea pedis (athlete’s foot), tinea cruris, and tinea corporis caused by <i>Trichophyton rubrum</i>, <i>Trichophyton mentagrophytes</i>, and <i>Epidermophyton floccosum</i>, in the treatment of cutaneous candidiasis (moniliasis), and in the treatment of tinea versicolor. |
| DrugBank Pharmacology: | Miconazole is an anti-fungal medication related to fluconazole (Diflucan), ketoconazole (Nizoral), itraconazole (Sporanox), and clotrimazole (Lotrimin, Mycelex). It is used either on the skin or in the vagina for fungal infections. Miconazole was approved by the FDA in 1974. Miconazole prevents fungal organisms from producing vital substances required for growth and function. This medication is effective only for infections caused by fungal organisms. It will not work for bacterial or viral infections. |
| DrugBank MoA: | Miconazole interacts with 14-α demethylase, a cytochrome P-450 enzyme necessary to convert lanosterol to ergosterol. As ergosterol is an essential component of the fungal cell membrane, inhibition of its synthesis results in increased cellular permeability causing leakage of cellular contents. Miconazole may also inhibit endogenous respiration, interact with membrane phospholipids, inhibit the transformation of yeasts to mycelial forms, inhibit purine uptake, and impair triglyceride and/or phospholipid biosynthesis. |
| Targets: | Cytochrome P450 51; Nitric oxide synthase, endothelial; Nitric oxide synthase, inducible; Nuclear receptor subfamily 1 group I member 2; Calcium-activated potassium channel; NA; Inward rectifier potassium channel; Voltage gated L-type calcium channel |
| Inclusion Criteria: |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class |
|---|